Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021

Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021

This review discusses reasons for prolonged use of anticoagulants after discharge of patients with COVID-19 without additional indication for anticoagulation. Data regarding rate of thrombotic and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented....

Full description

Bibliographic Details
Main Author:	I. S. Yavelov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2022-01-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	covid-19 venous thromboembolism deep vein thrombosis pulmonary embolism prevention heparin enoxaparin direct oral anticoagulants rivaroxaban apixaban betrixaban
Online Access:	https://www.rpcardio.online/jour/article/view/2620

Similar Items

Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
by: Konstantinos N. Aronis, et al.
Published: (2018-02-01)

The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants
by: Grzegorz Grześk, et al.
Published: (2021-08-01)

Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics
by: Luca Masotti, et al.
Published: (2013-12-01)

Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial
by: C. Michael Gibson, et al.
Published: (2018-01-01)

Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia
by: Evelien Krumb, et al.
Published: (2021-02-01)

Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment
by: Danielle Groat, et al.
Published: (2022-05-01)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
by: Song AB, et al.
Published: (2019-06-01)

Apixaban: An oral anticoagulant having unique mechanism of action with better safety and efficacy profile
by: Z A Fazeel
Published: (2016-01-01)

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01)

Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
by: Attard LM, et al.
Published: (2022-10-01)

The treatment of venous thromboembolism with new oral anticoagulants
by: Davide Imberti
Published: (2013-12-01)

Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series
by: Julie Carré, et al.
Published: (2021-08-01)

Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial
by: Seyed Hamid Borsi, et al.
Published: (2021-07-01)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
by: V. I. Petrov, et al.
Published: (2016-12-01)

VENOUS THROMBOEMBOLISM IN CANCER: AN UPDATE OF TREATMENT AND PREVENTION IN THE ERA OF NEWER ANTICOAGULANTS
by: Waqas Qureshi, et al.
Published: (2016-07-01)

Fatigue after initiating rivaroxaban for venous thromboembolism
by: Tina Margrethe Karlsvik, et al.
Published: (2020-05-01)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
by: Pamela L. Lutsey, et al.
Published: (2019-10-01)

Heparin, Enoxaparin, and Mechanical Prophylaxis Utilization Evaluation in DVT Prophylaxis in a Major Teaching Hospital in West of Iran
by: Anali Ali Akbari, et al.
Published: (2021-12-01)

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management
by: Martina Mookadam, et al.
Published: (2015-01-01)

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
by: Omar A. Alshaya, et al.
Published: (2022-12-01)

Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study
by: Korayem GB, et al.
Published: (2023-01-01)

Assessment and predictors of inappropriate dose of direct oral anticoagulants
by: Mosaad O. Almegren
Published: (2024-01-01)

Efficacy and Safety of Enoxaparin versus New Oral Anticoagulants to Prevent Venous Thromboembolism after Total Hip Replacement: A Systematic Review and Meta-Analysis
by: Mohammed Farhan A Alfarhan
Published: (2022-01-01)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017-08-01)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017-08-01)

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)

Asymptomatic “breakthrough” thrombosis and anticoagulant “failure”: Keep calm and carry on
by: Sven R. Olson, et al.
Published: (2019-07-01)

A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01)

Thromboprophylaxis in Proximal Femur Fracture: A Pilot Survey among Practicing Orthopaedic Surgeons in India
by: Nayantara Srikanth, et al.
Published: (2023-09-01)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
by: Ming-Lung Tsai, et al.
Published: (2022-12-01)

HOW NEW APPROACHES TO THE TREATMENT OF PULMONARY EMBOLISM AFFECT THE OUTCOME OF THE DISEASE?
by: M. Y. Gilyarov, et al.
Published: (2017-12-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)

Enoxaparina en el tratamiento de la tromboembolia venosa: estudio observacional de práctica clínica habitual
by: Antoni Riera-Mestre, et al.
Published: (2021-04-01)

Prevention of recurrent deep-vein thrombosis
by: Andrew N Nicolaides
Published: (2019-01-01)

Utilization and prescribing patterns of direct oral anticoagulants
by: Whitworth MM, et al.
Published: (2017-03-01)

Choice and Duration of Anticoagulation for Venous Thromboembolism
by: Aroosa Malik, et al.
Published: (2024-01-01)

Expanding the possibilities of treatment and prevention of venous thromboembolic complications in cancer patients. The role of oral anticoagulants
by: R. A. Bredikhin, et al.
Published: (2022-10-01)

Safety and efficacy of a new thromboprophylaxis regiment for total knee and total hip replacement: a retrospective cohort study in 265 patients
by: Mohammad Amre Fallaha, et al.
Published: (2018-08-01)

Are outpatient anticoagulation management services the wave of the future (again)?
by: Bethany Samuelson Bannow
Published: (2022-05-01)